|Day Low/High||15.52 / 16.09|
|52 Wk Low/High||12.56 / 88.54|
Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased Endo International plc ("Endo" or the "Company") (NYSE: ENDP) securities between...
In a record year for acquisitions, 18 companies from across the spectrum were singled out by M&A professionals for doing deals that got results.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Endo International plc securities (NASDAQ:ENDP) from September 28, 2015 through November 2, 2016,...
Days after price fixing allegations go public over generic drugs, Taro posts financials showing net sales up thanks to, yes that's right, its U.S. generic drug business.
Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Endo International plc ("Endo" or the "Company") (Nasdaq: ENDP).
Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Endo International plc ("Endo" or the "Company") (Nasdaq: ENDP) concerning possible violations of federal securities laws between...
Which stocks have shown these patterns in the past week.
Investors have a buying opportunity because the damage by any criminal charges is far less than what is likely to be inflicted by the feds.
Here is the real story behind three equities that just took major hits. Are any of them value plays?
Thursday felt a lot like capitulation in this space. I was buying.
U.S. stock futures point lower on Friday ahead of the monthly U.S. jobs report; Starbucks' profit jumps but same-store sales are flat; GoPro tanks.
Holzer & Holzer, LLC is investigating whether certain statements made by Endo International PLC ("Endo International" or the "Company") (NASDAQ:ENDP) regarding its business and operations complied with federal...
The DOJ's investigation has been under way for at least two years and a number of companies have reported receiving subpoenas related to the investigation.
Endo (ENDP) and other generic drug makers could reportedly face charges by the Department of Justice by year-end.
The medical devices company is likely to stick to small- to mid- sized M&A unless it finds itself the target.